Raina Biosciences Unveils AI-Powered mRNA Platform GEMORNA, Enabling Superior Therapeutic Design

Raina Biosciences Inc., a Boston-based mRNA technology and therapeutics company, has unveiled groundbreaking data from its generative AI platform, GEMORNA, published in the journal Science. The findings demonstrate the platform’s ability to design novel mRNA sequences with significantly improved translational capacity and stability—key factors that enhance protein expression and therapeutic durability. The study, titled "Deep generative models design mRNA sequences with enhanced translational capacity and stability," represents a major advancement in mRNA engineering. Unlike traditional methods that rely on incremental optimization, GEMORNA leverages deep generative AI to rapidly generate entirely new mRNA sequences tailored for superior performance. This approach enables faster, more precise, and more effective drug discovery, expanding the potential of mRNA therapeutics beyond infectious disease vaccines. Jicong Cao, Ph.D., CEO and co-founder of Raina Biosciences, and the corresponding author of the paper, highlighted the platform’s foundation in over a decade of research in synthetic biology and artificial intelligence. “We are excited to collaborate with leading pharmaceutical and biotechnology companies to broaden the application of mRNA-based therapies,” Cao said. “As we advance our internal pipeline, GEMORNA positions us to accelerate the development of next-generation treatments.” Timothy Lu, M.D., Ph.D., chairman of Raina’s board and a former MIT professor, emphasized the transformative potential of the technology. “GEMORNA could be a game-changer for biopharma,” he said. “It opens the door to mRNA applications in complex therapeutic areas such as neoantigen cancer vaccines, in vivo CAR T-cell therapies, gene editing, and gene replacement treatments—domains where conventional mRNA design has faced significant limitations.” Raina Biosciences is a spinout from the Massachusetts Institute of Technology, founded by a team of experts with deep expertise in both mRNA therapeutics and artificial intelligence. The company’s mission is to revolutionize the mRNA landscape by leveraging AI to shorten development timelines, improve therapeutic efficacy, and unlock new treatment possibilities across a broad spectrum of diseases. With its innovative platform and strong scientific foundation, Raina is poised to play a pivotal role in advancing the next generation of mRNA-based medicines.